Next- and Third-Generation Sequencing Outperforms Culture-Based Methods in the Diagnosis of Ascitic Fluid Bacterial Infections of ICU Patients.
anaerobic bacteria
ascitic fluid infections
full length 16S rRNA sequencing
intensive care unit
metagenomics
molecular diagnostics
nanopore
next-generation sequencing
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
18 11 2021
18 11 2021
Historique:
received:
26
10
2021
revised:
15
11
2021
accepted:
15
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Infections of the ascitic fluid are serious conditions that require rapid diagnosis and treatment. Ascites is often accompanied by other critical pathologies such as gastrointestinal bleeding and bowel perforation, and infection increases the risk of mortality in intensive care patients. Owing to a relatively low success rate of conventional culture methods in identifying the responsible pathogens, new methods may be helpful to guide antimicrobial therapy and to refine empirical regimens. Here, we aim to assess outcomes and to identify responsible pathogens in ascitic fluid infections, in order to improve patients' care and to guide empirical therapy. Between October 2019 and March 2021, we prospectively collected 50 ascitic fluid samples from ICU patients with suspected infection. Beside standard culture-based microbiology methods, excess fluid underwent DNA isolation and was analyzed by next- and third-generation sequencing (NGS) methods. NGS-based methods had higher sensitivity in detecting additional pathogenic bacteria such as Our results show that, in ascitic fluid infections, NGS-based methods have a higher sensitivity for the identification of clinically relevant pathogens than standard microbiological culture diagnostics, especially in detecting hard-to-culture anaerobic bacteria. Patients with such infections may benefit from the use of NGS methods by the possibility of earlier and better targeted antimicrobial therapy, which has the potential to lower the high morbidity and mortality in critically ill patients with ascitic bacterial infection.
Identifiants
pubmed: 34831447
pii: cells10113226
doi: 10.3390/cells10113226
pmc: PMC8617993
pii:
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 413517907
Organisme : Faculty of medicine research commission at the University of Freiburg
ID : 3095088718
Références
Antibiotics (Basel). 2020 Nov 18;9(11):
pubmed: 33217968
F1000Res. 2016 Jun 24;5:1492
pubmed: 27508062
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Trends Microbiol. 2014 May;22(5):267-74
pubmed: 24698744
Nat Med. 2021 Jan;27(1):115-124
pubmed: 33169017
Sci Rep. 2018 Feb 28;8(1):3812
pubmed: 29491401
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
Crit Care Med. 2010 Apr;38(4):1045-53
pubmed: 20048677
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):533-41
pubmed: 20238135
J Pathol Clin Res. 2020 Apr;6(2):97-106
pubmed: 31944633
Hepatology. 1987 Jan-Feb;7(1):122-8
pubmed: 3804191
Hepatology. 2005 Mar;41(3):422-33
pubmed: 15723320
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Rev Esp Enferm Dig. 2011 May;103(5):255-63
pubmed: 21619390
Nat Med. 2019 Apr;25(4):679-689
pubmed: 30936547
BMC Bioinformatics. 2021 Mar 25;22(1):160
pubmed: 33765910
Sci Rep. 2020 May 6;10(1):7622
pubmed: 32376847
Ther Adv Chronic Dis. 2015 May;6(3):124-37
pubmed: 25954497
Nat Biotechnol. 2017 Nov;35(11):1069-1076
pubmed: 28967887
World J Emerg Surg. 2013 Jan 08;8(1):3
pubmed: 23294512
Euroasian J Hepatogastroenterol. 2015 Jul-Dec;5(2):131-133
pubmed: 29201710
PLoS One. 2014 May 16;9(5):e97876
pubmed: 24837716
Clin Microbiol Rev. 2013 Jul;26(3):604-30
pubmed: 23824374
Front Med (Lausanne). 2021 Aug 05;8:693652
pubmed: 34422858
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Sci Rep. 2017 Jul 18;7(1):5657
pubmed: 28720805
Cureus. 2018 Mar 1;10(3):e2253
pubmed: 29721399
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Nat Commun. 2019 Nov 6;10(1):5029
pubmed: 31695033
Nat Biotechnol. 2020 Sep;38(9):1079-1086
pubmed: 32341564
Sci Rep. 2021 Jan 18;11(1):1727
pubmed: 33462291
Clin Infect Dis. 1996 Sep;23(3):486-94
pubmed: 8879770
Nat Biotechnol. 2019 Jul;37(7):783-792
pubmed: 31235920
Bioinformatics. 2018 Aug 1;34(15):2666-2669
pubmed: 29547981
Aliment Pharmacol Ther. 2015 Jun;41(11):1116-31
pubmed: 25819304
Mucosal Immunol. 2021 Jan;14(1):113-124
pubmed: 32433514
mSphere. 2021 Feb 24;6(1):
pubmed: 33627512
Sci Rep. 2016 Apr 26;6:25001
pubmed: 27112233
Clin Gastroenterol Hepatol. 2014 Mar;12(3):496-503.e1
pubmed: 23978348
Diagn Pathol. 2020 Apr 27;15(1):41
pubmed: 32340617
J Microbiol Immunol Infect. 2015 Oct;48(5):504-9
pubmed: 25305707
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Hepatology. 2009 Jun;49(6):2087-107
pubmed: 19475696
Crit Care Med. 2003 Aug;31(8):2228-37
pubmed: 12973184
BMC Biol. 2014 Nov 12;12:87
pubmed: 25387460
Mol Ecol Resour. 2019 Jul;19(4):982-996
pubmed: 30887686